

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

This rule would go beyond already controversial genetically modified organisms (GMOs) to encompass hundreds of new products of new gene and genome editing techniques. (Photo: Andrea Seaman/flickr/cc)
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."